Latest Industry News & Trends
Recently Added
J&J Vision Launches TECNIS Synergy IOL in Europe, Australia, and New Zealand
Johnson & Johnson Vision launched its TECNIS Synergy intraocular lens on Sept. 16 in Paris. The IOL is available in Europe, Australia, and New Zealand. The company describes the Synergy as a presby...
BVI’s PhysIOL Launches FineVision Triumf EDOF Trifocal IOL
Beaver-Visitec International announced Sept. 12 that its PhysIOL subsidiary launched the FineVision Triumf trifocal extended depth of focus (EDOF) IOL in Europe in conjunction with the 2019 Congres...
Alcon Launches Two Enhancements to WaveLight Refractive Suite
Alcon announced Sept. 9 that it has launched two additions to its WaveLight Refractive Suite for LASIK surgery: complementary diagnostic software intended to provide the most enhanced corneal profi...
Adverum Reports Positive Results from First Cohort in Phase I Trial of Gene Therapy to Treat Wet AMD
Adverum Biotechnologies announced on Sept. 11 positive 24-week clinical data from the first cohort of six patients treated with a one-time intravitreal (IVT) dose of ADVM-022 in the company’s Phase...
Aurinia Looks to Raise $40 Million with ‘At the Market’ Offerings
Aurinia Pharmaceuticals announced Sept. 13 that it would sell, through periodic “at the market” (ATM) offerings, common shares with an aggregate offer price of up to $40 million. Aurinia said it in...
CorNeat Vision Completes Preclinical Phase for Synthetic Cornea and Scleral Patch
CorNeat Vision, of Israel, announced Sept. 9 that it had completed the preclinical stage for its investigational corneal implant and synthetic, nondegradable scleral patch. The company’s product ca...
Lineage Cell Therapeutics Sells OnoCyte Shares, Raises $6.6 Million
Lineage Cell Therapeutics announced Sept. 11 that it had sold 4 million shares of common stock of OncoCyte at $1.66 per share. Gross proceeds from the sale were $6.6 million. The Carlsbad, Californ...
MST Innovations Introduces the Scleral IOL Fixation Solutions Pack
MicroSurgical Technology has introduced its Scleral IOL Fixation Solutions Pack, designed to streamline the double-needle scleral IOL fixation technique with new instruments packaged together to su...
Nevakar Completes Enrollment in Phase III Study of Drug Candidate to Slow Myopia in Children
.jpg)
Nevakar announced Sept. 11 that it had completed enrollment in a Phase III study evaluating the ability of its candidate NVK-002 to slow the progression of myopia in children. NVK-002 is a preserva...
Canon Xephilio Optical Coherence Tomography Device Gets FDA 510(k) Clearance
Canon’s Xephilio OCT-A1 Optical Coherence Tomography device has been cleared for sale in the US, the company announced Sept. 17. The Xephilio OCT-A1 has a scanning speed of 70 thousand A-scans per ...
Vertical Pharmaceuticals Files NDA for Candidate for Droopy Eyelid
Vertical Pharmaceuticals announced Sept. 18 that it has submitted a new drug application to the US FDA for RVL-1201, its oxymetazoline hydrochloride ophthalmic solution for acquired blepharoptosis,...
Wize Pharma Reaches Licensing Deal for Ophthalmic Nonviral Gene Therapy Technology
Wize Pharma, of Israel, has entered into an exclusive license agreement with US-based Copernicus Therapeutics for rights to develop and commercialize products based on Copernicus’ nonviral gene the...
Past News Stories
SI-BONE’s iFuse Receives Coverage
SI-BONE announced Sept. 3 that its minimally invasive sacroiliac joint fusion device, iFuse, received coverage from Wellmark Blue Cross Blue Shield. This system covers over 1.5 million members acro...
JAAOS Article Reports Laser Spine Surgery Poses More Risks Than Benefits
The Journal of the American Academy of Orthopaedic Surgeons (JAAOS) published an article Sept. 1 by Kris Radcliff, MD, et al., stating that laser spine surgery is not supported by clinical data. Th...
WishBone Signs Agreement to Distribute OsteoCrete
WishBone Medical signed a private-label distribution agreement with Bone Solutions for OsteoCrete, a resorbable, magnesium-based bone void filler, the company announced Aug. 15. This agreement give...
CARLSMED Merges With Precisive Surgical
Medical technology company CARLSMED announced July 17 that it completed a merger with Precisive Surgical, a spine imaging company. The end goal of this deal is to create a complete, personalized su...
Cataract Surgery Products Continue to be the Main Single-Use Surgical Device Sales Driver
.jpg)
The world’s aging population--leading to steady growth in cataract surgeries--and rising concerns over cross-contamination are key factors that will drive healthy growth in the single-use ophthalmi...
Cigna to Cover Full Price of Luxturna, Zolgensma Gene Therapies in the US
Cigna Health will cover the price of gene therapies Luxturna and Zolgensma in the US, ensuring patients have no out-of-pocket costs, the health service company announced Sept. 5. To do so, Cigna ha...
Keranova Raises $26.5 Million in Second Round for Cataract Surgery Technology
France-based Keranova announced Sept. 10 that it raised $26.5 million (€24 million) in a second round of financing. The company is developing a system designed to combine several steps of cataract ...
Biotissue Expands Sales Force Following $82.25M Financing by Parent TissueTech
Biotissue announced Sept. 11 that it is expanding its sales force for its cryopreserved amniotic membrane products for ophthalmic use through funding raised by parent TissueTech. TissueTech reporte...
Novartis Announces EU Approval of Lucentis for Preterm Infants with Retinopathy of Prematurity
The Swiss company Novartis announced Sept. 6 the European approval of Lucentis (ranibizumab) for preterm infants with retinopathy of prematurity (ROP), making it the first and only licensed drug tr...
Kowa Submits IND to US FDA to Study its Glanatec Rho Kinase Inhibitor for Corneal Endothelial Diseases
The Japanese company Kowa announced Sept. 3 that it had submitted an investigational new drug (IND) application to the US FDA to begin a Phase II study for its ripasudil hydrochloride hydrate Rho k...
Allergan and Molecular Partners Announce Acceptance of Applications in US, EU for Abicipar Pegol in Patients with Wet AMD
.jpg)
Allergan and Molecular Partners announced Sept. 9 that the US FDA had accepted a biologics license application and the European Medicines Agency (EMA) had validated a marketing authorization applic...
Ocuphire Completes Enrollment in Phase II Trials of Nyxol Drops for Glaucoma
Ocuphire Pharma, of Farmington Hills, Michigan, announced Sept. 4 that it had successfully enrolled 39 glaucoma patients at five US sites from late May to August 2019 for the ORION-1 Phase IIb tria...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.